Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries.

Alopecia areata Burden Europe Patient-reported outcomes Real-world Severity Symptoms

Journal

Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 07 06 2023
accepted: 09 10 2023
medline: 27 10 2023
pubmed: 27 10 2023
entrez: 27 10 2023
Statut: ppublish

Résumé

Alopecia areata (AA) can negatively affect quality of life (QoL) and is associated with increased prevalence of anxiety and depression (vs people without AA). This study compared physician-assessed and patient self-rated severity of AA in a European sample and described the patient-reported burden of AA stratified by physician-assessed severity. Real-world data were collected from the Adelphi Real World AA Disease Specific Programme™, a retrospective point-in-time cross-sectional survey of dermatologists and their adult patients with AA in five European countries (France, Germany, Italy, Spain, UK). Physicians provided clinical data and an AA severity assessment, according to their own definition of 'mild', 'moderate' and 'severe'. Patients were invited to provide their perception of AA severity and completed patient-reported outcome (PRO) questionnaires, including Skindex-16 for AA (Skindex-16 AA), EuroQol-5-dimension questionnaire 5-level (EQ-5D-5L), Hospital Anxiety and Depression Scale and the Work Productivity and Activity Impairment Questionnaire. Data for 2083 patients were collected by 239 physicians; 561 of these patients completed PRO questionnaires. In 78.5% of cases with available data (N = 549), there was alignment between patient and physician-rated AA severity (severity was rated higher by physicians in 15.7% of cases, by patients in 5.8% of cases). Data from all PRO instruments showed an increase in patient-reported burden and work and activity impairment with increasing physician-rated AA severity. For the Skindex-16 AA, the Emotions scale had the worst scores; anxiety/depression was the EQ-5D-5L dimension with the highest percentages of patients reporting any perceived problem. These data highlight the significant impact that AA can have beyond hair loss, especially for patients with severe AA. There was substantial physician-patient alignment on severity assessment. Higher physician-rated AA severity was associated with higher levels of patient-reported disease burden, including anxiety and depression, and work and activity impairment. These data may help inform appropriate treatment strategies. Alopecia areata (AA) can negatively affect quality of life and is associated with increased prevalence of anxiety and depression (vs people without AA). This study used surveys of adult patients with AA in Europe and their dermatologists to compare how doctors and patients assess AA severity. We also looked at how patients rate the overall burden and broader effects of AA (not just hair loss) according to whether their doctor classed their AA as ‘mild’, ‘moderate’ or ‘severe’. Data for 2083 patients were collected by 239 doctors; 561 patients completed questionnaires about their AA and its potential effects on their quality of life, mental health and ability to work or perform other activities. In 78.5% of cases (from 549 patients with both patient and doctor-rated severity), patients and their doctors agreed on the same AA severity category (mild, moderate or severe). However, in 15.7% of cases, doctors rated AA severity as being higher than reported by the patient, and in 5.8% of cases the patient classed their AA as being more severe than reported by the doctor. Data from patient questionnaires showed that the burden associated with AA was higher in patients with more severe AA (as per their doctor’s own definition of severity); anxiety/depression was the most commonly reported problem related to quality of life. This study highlights the significant impact that AA can have beyond hair loss, especially for patients with severe AA. Information from this study may help to inform appropriate treatment strategies for people with AA.

Autres résumés

Type: plain-language-summary (eng)
Alopecia areata (AA) can negatively affect quality of life and is associated with increased prevalence of anxiety and depression (vs people without AA). This study used surveys of adult patients with AA in Europe and their dermatologists to compare how doctors and patients assess AA severity. We also looked at how patients rate the overall burden and broader effects of AA (not just hair loss) according to whether their doctor classed their AA as ‘mild’, ‘moderate’ or ‘severe’. Data for 2083 patients were collected by 239 doctors; 561 patients completed questionnaires about their AA and its potential effects on their quality of life, mental health and ability to work or perform other activities. In 78.5% of cases (from 549 patients with both patient and doctor-rated severity), patients and their doctors agreed on the same AA severity category (mild, moderate or severe). However, in 15.7% of cases, doctors rated AA severity as being higher than reported by the patient, and in 5.8% of cases the patient classed their AA as being more severe than reported by the doctor. Data from patient questionnaires showed that the burden associated with AA was higher in patients with more severe AA (as per their doctor’s own definition of severity); anxiety/depression was the most commonly reported problem related to quality of life. This study highlights the significant impact that AA can have beyond hair loss, especially for patients with severe AA. Information from this study may help to inform appropriate treatment strategies for people with AA.

Identifiants

pubmed: 37889388
doi: 10.1007/s13555-023-01057-0
pii: 10.1007/s13555-023-01057-0
pmc: PMC10689682
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3121-3135

Informations de copyright

© 2023. The Author(s).

Références

J Patient Rep Outcomes. 2020 Sep 11;4(1):76
pubmed: 32914253
Br J Dermatol. 2012 May;166(5):916-26
pubmed: 22524397
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Dermatol. 2022 Jun;49(6):575-583
pubmed: 35343611
J Am Acad Dermatol. 2012 Mar;66(3):e97-102
pubmed: 21601948
J Eur Acad Dermatol Venereol. 2023 Jan 27;:
pubmed: 36708097
J Eur Acad Dermatol Venereol. 2012 Feb;26(2):213-8
pubmed: 22280509
J Invest Dermatol. 2022 Oct;142(10):2646-2650.e3
pubmed: 35331716
Curr Med Res Opin. 2008 Nov;24(11):3063-72
pubmed: 18826746
J Dtsch Dermatol Ges. 2022 Jan;20(1):59-90
pubmed: 35040577
J Am Acad Dermatol. 2023 May;88(5):1040-1050
pubmed: 31163237
Dermatol Ther (Heidelb). 2022 Apr;12(4):825-834
pubmed: 35357658
Dermatol Ther (Heidelb). 2023 Jan;13(1):285-298
pubmed: 36484916
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Int J Womens Dermatol. 2017 Sep 04;4(2):91-94
pubmed: 29872683
J Am Acad Dermatol. 2021 Jul;85(1):162-175
pubmed: 32561373
J Cutan Med Surg. 2001 Mar-Apr;5(2):105-10
pubmed: 11443481
Front Med (Lausanne). 2022 Nov 29;9:1054898
pubmed: 36523776
Br J Dermatol. 2017 May;176(5):1170-1178
pubmed: 28032340
Skin Appendage Disord. 2019 Aug;5(5):293-298
pubmed: 31559253
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Br J Dermatol. 2022 Jul;187(1):73-81
pubmed: 35157313
J Am Acad Dermatol. 2019 Feb;80(2):466-477.e16
pubmed: 30031145
Dermatol Ther (Heidelb). 2022 Apr;12(4):989-997
pubmed: 35352323
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Sergio Vañó-Galván (S)

Ramón y Cajal University Hospital, University of Alcala, Madrid, Spain.

Ulrike Blume-Peytavi (U)

Department of Dermatology, Venerology and Allergology, Charité-Universitätsmedizin, Berlin, Germany.

Paul Farrant (P)

Department of Dermatology, Brighton General Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.

Pascal Reygagne (P)

Centre Sabouraud, Hôpital Saint-Louis, Paris, France.

Erin Johansson (E)

Eli Lilly and Company, Indianapolis, IN, USA.

Catherine Reed (C)

Eli Lilly and Company, Indianapolis, IN, USA.

Simran Marwaha (S)

Adelphi Real World, Macclesfield, Cheshire, UK.

Frederick Durand (F)

Eli Lilly and Company, Indianapolis, IN, USA.

Bianca Maria Piraccini (BM)

Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni 15, 40138, Bologna, Italy. biancamaria.piraccini@unibo.it.
Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 1, 40138, Bologna, Italy. biancamaria.piraccini@unibo.it.

Classifications MeSH